Skip to content
DataLookout
Menu

NCT07933328

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percent Change from Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat fraction (MRI-PDFF)
Timeframe: At Week 52
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Through Week 64
Severity of TEAEs
Timeframe: Through Week 64

Secondary (5)

Change from Baseline in Aspartate Aminotransferase (AST)
Change from Baseline in Alanine Aminotransferase (ALT)
Change from Baseline in FibroScan Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE)
Change from Baseline in Enhanced Liver Fibrosis (ELF)
Change from Baseline in FibroScan Controlled Attenuation Parameter (CAP)

Arms and interventions

ALN-CIDEB Dose Level 1Experimental
ALN-CIDEB Dose Level 2Experimental
PlaceboPlacebo comparator

Drugs: ALN-CIDEB, Placebo